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1. Introduction 
Carcinoma of the pancreas is a devastating disease. The incidence of pancreatic carcinoma 
has increased in recent decades, yet the treatment outcome for this disease remains 
unsatisfactory. Despite the introduction of new therapeutic techniques and adoption of 
aggressive combined treatment modalities, such as external beam radiotherapy (EBRT) and 
chemotherapy, the prognosis of pancreatic carcinoma remained to be extremely poor, with a 
mortality rate of more than 90% (Geer & Brennan, 1993). Pancreatic cancer responds poorly 
to surgical resection or chemotherapy, moreover only 10–20% of patients are candidates for 
curative surgical resection, and even with resection, long term survival still remains poor 
(Levin et al., 1978; Crile, 1970), therefore, the remaining patients have to seek alternative 
therapeutic options (Joyce et al., 1990). Biliary and gastric bypass have been used for 
palliation in unresectable pancreatic carcinomas and median survival in these patients was 
often 5–6 months (Thompson & Nagorney, 1986; Schwarz & Beger, 2000; Khan et al., 2010). 
However most of pancreatic carcinoma was diagnosed in the locally advanced or metastatic 
stage, both local control and management of distant metastases are the major factors that 
affect the prognosis of such patients. More recently, EBRT and chemotherapy have been 
standard adjuvants for locally advanced pancreatic carcinoma. External beam radiotherapy 
therapy, one of the options, is usually regarded as insensitive to pancreatic cancer and 
associated with more systemic side effects, although it can relieve pain in up to 50–85% of 
patients (Minsky et al., 1988). Also EBRT alone has failed to control disease progression and 
yields a median survival of 5.5–7 months (Bodner et al., 2000; Nag et al., 2006). The 
introduction of intraoperative electron beam radiotherapy, combined with EBRT and 
chemotherapy, has also failed to significantly improve long-term results, with recent studies 
reporting median survival rates of 7–16 months (Blasko et al., 2002; Wang et al., 2010; 
Cengiz et al., 2008; Monk et al., 2002). Despite the availability of many treatments, there was 
currently no consensus regarding the optimal therapeutic modality for unresectable 
pancreatic carcinomas. Therefore, it is necessary to investigate new techniques that may 
improve the prognosis. It has been reported that compared with external irradiation 
therapy, 5− Fu chemotherapy combined with radiotherapy prolonged the median survival 
time of patients with local advanced pancreatic cancer from 23 weeks to 42-44 weeks 
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(Mattiucci et al., Furuse et al., 2010; Kouloulias et al., 2002). However, there are few reports 
on interstitial implantation of radioactive seeds in the treatment of pancreatic cancer (Sun et 
al., 2005; Mohiuddin et al., 1992).Interstitial brachytherapy has been reported to be a useful 
method for local control of malignant pancreatic tumors (Takacsi et al., 2002; Enomoto et al., 
2006). After placement of the radioactive seeds, the target tissue is exposed to a steady 
emission of gamma rays, which leads to localized ablation. Interstitial brachytherapy has 
been applied to unresectable pancreatic cancers in an attempt to maximize local tumor dose 
and minimize radiation dose to the surrounding normal structures. Therefore, radioactive 
iodine-125 seed implantation is another choice for treatment of malignant tumors, which is 
widely applied for its curative effect, minimal surgical trauma, and few complications 
(Ebara et al., 2008; Siegel et al., 1988; Holm et al., 1981). 
2. Advantages of biological effects of radioactive iodine-125 seed 
Advantages of 125I seeds over other forms of radiotherapy are as follows: 
1. Radiation from seeds is characterized by attenuation over short distance outside the 
target area and low grade of depth dose, which can keep a higher accumulative dose 
(up to 160 Gy) within the tumor. Unfortunately, serious complications such as radiation 
hepatitis can occur when the absorbed dose is less than 35 Gy as in traditional 
radiotherapy.  
2. External radiotherapy in fractionation is only effective in cells in some phases of cell 
cycle. During the interval of irradiation, effect of radiotherapy is decreased because cells 
in the stationary phase enter into the mitotic stage. The 125I seeds can kill tumor cells 
continually by keeping cells in the resting period and causing tumor stem cell apoptosis 
(Wang et al., 2010).  
3. Deficiency of oxygen is a bottleneck of conventional external radiotherapy. Sensitive 
phase cells will be killed by the accumulated damaging effect of irradiation. However, 
cells deficient in oxygen avoid apoptosis by entering the sensitive phase.  
4. Inhomogeneous radiation absorption occurs in the traditional method due to 
respiratory movements, which decrease the therapeutic volume. By contrast, the 
therapy using radioactive seeds is not affected by respiratory movements; the 
probability of therapeutic volume loss is obviously tiny.  
5. Implantation of low energy, radioactive seeds is able to decrease the metastasis of 
tumor by changing the immunophenotype of tumor cells. Some research indicated that 
the radiobiological effect of radioactive seeds was superior to that of three dimensional 
conformal radiation (Mazeron et al., 2003). 
3. Indications 
1. Neutrophil leukocyte 3×109/L or higher, platelets 70×109/L or higher, and  
hemoglobin 90 g/L or higher in peripheral blood. 
2. Prothrombin index (PI) greater than 50% and partial thromboplastin time (PTT) less 
than 50 s; kidney function within normal range. 
3. Karnofsky physical scores (KPS) greater than or equal to 60. 
4. With pathologically confirmed an advanced stage of pancreatic cancer. 
5. Advanced pancreatic cancer was unable to undergo open surgery due to clinical or 
personal reasons. 
www.intechopen.com
Clinical Application of Image-Guided Iodine-125 Seed  
Implantation Therapy in Patients with Advanced Pancreatic Cancer 
 
111 
6. Tumor maximum diameter of less than 6cm. 
7. Previous course of chemotherapy were eligible.  
4. Contraindications 
1. Pregnant women and patients with distant metastasis (e. g. liver, lung). 
2. Tumor maximum diameter greater than 6cm. 
3. Expected survival time of less than 3 months. 
4. Systemic failure. 
5. Bleeding tendency. 
6. Prothrombin time 3 seconds longer than the control were excluded. 
7. Any previous irradiation or external radiotherapy were excluded. 
5. Preoperative preparation 
5.1 I seed sources 
The 125I sealed seed sources were supplied by XinKe Pharmaceutical Ltd, Shanghai. For the 
seed implantation we used 18-G implantation needles and turntable implantation gun 
(XinKe Pharmaceutical Ltd, Shanghai, China). The 125I seeds were manufactured from silver 
rods, which absorbed 125I, and were enclosed in a titanium capsule welded by laser. The 
diameter of each seed was 0.8 mm, the length was 4.5 mm, and thickness of the wall of the 
titanium capsule was 0.05 mm (Fig.1,2). The 125I produces gamma rays (5% of 35 keV, 95% of 
28 keV) with a half-life of 59.6 days, half-value thickness of 0.025 mm of lead, penetration of 
17 mm, incipient rate of 7 cGy/h, a mean radioactivity of 0.694±0.021 mCi (25.6 MBq), and 
activities of 0.5–0.9 mCi. 
 
 
Fig. 1. Radioactive 125I seeds  
 
 
Fig. 2. Radioactive 125I seed profile chart 
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5.2 Diagnosis of pancreatic cancer 
Imaging methods were adopted for the clinical diagnosis of pancreatic cancer. Patients were 
first diagnosed by conventional computed tomography (CT) or magnetic resonance imaging 
(MRI), and by thin slice helix CT 10 days before implantation of seeds. Histological 
confirmation of the diagnosis was achieved by CT-guided, EUS−guided fine needle 
aspiration (FNA) 1 week before implantation. FNA has been accepted as a gold standard 
(Volmar et al., 2005; Gupta et al., 2002; Dickey et al., 1986; Mueller, 1993; Brandt et al., 1993) 
in the diagnosis of pancreatic cancer. Furthermore, patients had an abnormal serum CA19-9 
level (higher than 37 U/ mL, 519±439 U/mL). All enrolled patients were diagnosed with 
pancreatic carcinoma before seed implantation. 
5.3 Treatment planning 
Dose distribution was calculated using a Fudan TPS2.00 brachytherapy planning system 
(Fudan University, Shanghai, China) based on the American Association of Physicists in 
Medicine TG43 brachytherapy formalism (Chen et al., 2008).The total volume of each tumor 
was calculated according to the CT image with the treatment planning system (TPS) before 
implantation (Cengiz et al., 2008). Patients underwent a detailed tumor volume study using 
CT scans 1–2 weeks before seed implantation. Images of each pancreatic carcinoma were 
obtained at 5 mm intervals. The radiation oncologist and surgeons together outlined the 
gross tumor volume (GTV) on each image and planning target volume (PTV) included GTV 
plus 0.5 – 1.0 cm peripheral tissue. These tracings were digitized and scanned to define the 
tumor volume, from which the D90 of 60–140 Gy for 125I seed irradiation, with the median of 
120 Gy and the number of 125I seeds to be implanted could be calculated. The D90 was 
prescribed in a way that at least 90% of the tumor volume received the reference dose. In 
brief, the information from CT or MRI images was reconstructed into a three-dimensional 
form, and the precise margin of the tumor was outlined to facilitate the calculation of tumor 
matched peripheral dose (MPD). The expected number of implanted seeds was calculated 
according to the modified level formula (Monk et al., 2002). The 125I with a nominal activity 
of 0.5–0.8 mCi/seed and a diameter of less than 1 mm was used as a radiation source and 
implanted into pancreatic tumor under image guidance, at a spacing of 1 cm.  
5.4 Calculation of the number of seeds needed for implantation 
The total volume of each tumor was calculated according to the CT image with the 
treatment planning system (TPS) before implantation (Bodner et al., 2000). In brief, the 
information from CT or MRI images was reconstructed into a three−dimensional form, and 
the precise margin of the tumor was outlined. An isodose curve and dose-volume histogram 
were drawn to concentrate the radioactivity in the target area. The expected number of 
implanted seeds was then calculated according to the modified Cevec formula (Monk et al., 
2002) as follows:  
Number of seeds needed 
 
[½ ] /
3
Tumor length width heigth in 5 the mean activity per seed in   cm mCi
 (1) 
In practice, to reach the maximum radiation effect, the number of seeds implanted was 15% 
more than needed. The seeds were sterilized by immersing in 2% glutaraldehyde solution 
for 20-30 minutes, then washed and placed into the specially designed releasing device. 
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During the course of implantation, and the seeds were released and deposited in the target 
position. 
5.5 Pretreatment evaluation 
In most cases, the initial request for a radiotherapy consultation occurred at the time of 
exploratory laparotomy, so a detailed preimplant evaluation by the radiation oncologist was 
not possible; however, in all cases, the patients were carefully studied by the surgical team 
preoperatively. All patients were evaluated by comprehensive medical history, physical 
examination, and standard presurgical studies including complete blood count, serum 
chemistries, liver function tests, urine analysis, and chest X-ray, as well as the following 
special imaging studies: abdominal ultrasound, computerized tomography, and MRI. 
5.6 Patient preparation 
All patients signed written informed consent before the study and were informed of 
potential benefits and risks. The whole study protocol was approved by the Ethics 
Committee. 
Patients fasted for 24 h prior to the operation, and oral laxatives were given 12 h before the 
procedure. Pancreatic secretion was inhibited by medication 24 h before the operation to 
reduce the rates of complications. For patients with jaundice, percutaneous transhepatic 
cholangiodrainage (PTCD) was scheduled first in order to relieve symptoms, improve liver 
function, and reduce the surrounding edema, after which seeds implantation was 
performed. 
6. Image-guided interstitial brachytherapy protocol 
6.1 CT-guided interstitial brachytherapy protocol 
The total volume of each tumor was calculated according to the CT image with the 
treatment planning system (TPS) before implantation (Cengiz et al., 2008). In brief, the 
information from CT or MRI images was reconstructed into a three-dimensional form, and 
the precise margin of the tumor was outlined to facilitate the calculation of tumor matched 
peripheral dose (MPD). The expected number of implanted seeds was calculated according 
to the modified level formula (Monk et al., 2002). In practice, to reach the maximum 
radiation effect, the number of seeds implanted was 15% more than needed. Implantation 
was guided by CT according to our TPS. The 125I with a nominal activity of 0.5–0.9 
mCi/seed and a diameter of less than 1 mm was used as a radiation source and implanted 
into pancreatic tumor under fluoroscopy CT guidance, at a spacing of 1 cm, avoiding 
puncturing vessels, pancreatic duct, and other nearby organs. Patients fasted for 24 h prior 
to the operation, and oral laxatives were given 12 h before the procedure. Pancreatic 
secretion was inhibited by medication 24 h before the operation to reduce the rates of 
complications. Sufficient breath training was given to ensure steady breath movement 
during the procedure. All the brachytherapy implants were performed in a standard CT 
room under local anesthesia. CT imaging was taken at intervals of 5 mm. The distance 
between the adjacent implantation needles was approximately 1 cm each. Transgression of 
the bowel during the puncture did not result in substantial complications in our study. 
However, a safer approach is achieved by transversing the stomach. Intestine and colon 
should be avoided especially when using large-bore needles. Repeated CT with the 
implantation needles in place permitted adjustment of depth and angle of needle direction. 
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Two to five seeds per needle were loaded, and seeds were released every 5–10 mm apart 
upon withdrawing the needles. For patients with jaundice, percutaneous transhepatic 
cholangiodrainage (PTCD) was scheduled first in order to relieve symptoms, improve liver 
function, and reduce the surrounding edema, after which seeds implantation was 
performed. Afterwards the implantation puncture site was bandaged and compressed to 
achieve hemostasis. Patients were kept in radiooncology/interventional ward for 4 full 
days. 
6.2 EUS−guided interstitial brachytherapy protocol 
All eligible patients underwent implantation of iodine−125 seeds. The operator wore a lead 
apron. A linear−array therapeutic echo endoscope (EG3830UT; Pentax Precision 
Instruments, Orangeburg, New York, USA) was inserted into the proximal stomach. The 
maximal diameter of the tumor was measured by real−time sector ultrasound (Olympus 
China Co. Ltd, Shanghai, China), with a frequency of 5-7.5 MHz. EUSwas performed to 
show the conformation of the pancreatic tumor and EUS images were captured by 
computer. The tumor volumes were calculated using EUS and CT images and 3Ddiameters 
of the tumors and treatment plan system software (Zhiye Medical Software Co., Shenyang, 
China). The minimum peripheral dose was then set to 140 Gy and the dose of every seed 
was entered into the software. The number of implants required was calculated by the 
software and the distribution plan maps were drawn: the experienced operator would then 
know the distance and direction of every target site from the center of the tumor. Iodine−125 
radioactive seeds could be inserted easily through the channel of a 19−gauge therapeutic 
needle (Wilson−Cook Medical Inc., Win− ston−Salem, North Carolina, USA). When the 
needle was inserted into the target site under EUS guidance, the stylet was removed and a 
seed was inserted into the needle; the stylet of the needle was then advanced to push the 
seed forward, and the seed was released from the needle and implanted into the tissue. This 
implantation procedure was repeated until all the seeds were implanted into target sites 
according to the treatment plan. The lesion was observed by multi−slice scanning, and the 
relationship between the surrounding vasculature and the tumor was then identified. The 
puncture points and method of puncturing were determined by color Doppler technology to 
prevent injuring the pancreatic duct or the vasculature of the pancreas.  
In principle, the seeds should be in a line and parallel to each other. The distance between 
each seed should be the same (1.0~1.5 cm). The distribution of seeds should be denser in the 
peripheral area so as to avoid high−dose−induced complications. 
6.3 Intraoperative ultrasound-guided interstitial brachytherapy protocol 
After the diagnosis of pancreatic cancer had been established by biopsy intraoperation, 
tumor volume was measured during laparotomy by intraoperative ultrasonography 
utilizing a megahertz linear probe. Guided by ultrasound, 18-gauge needles were implanted 
into mass and spaced in a parallel array at intervals of 1.0 cm, extending at least 0.5~1 cm 
beyond the margins of the pancreatic lesions. During the placement of the needles, care was 
taken to avoid the needles from the pancreatic duct, small blood vessels, and the adjacent 
transverse colon at least 1 cm. After needles were implanted, 125I seeds were implanted 
using a Mick-applicator and the spacing was maintained at 1.0 cm intervals. The number of 
125I seeds implanted ranged from 10 to 75, with the median number implanted of 38. The 
specific activity of 125I ranged from 0.40 to 0.60 mCi per seed, and the total isotope 
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radioactivity implanted ranged from 4 to 37.5 mCi. An omental fat pad was placed over the 
implanted volume to protect the gastric and transverse colon mucosa from irradiation.  
7. Post-implant adjuvant therapy 
7.1 Chemotherapy 
Patients who gave consent to chemotherapy received combined treatment with gemcitabine 
1.0 g/m2 (body surface area) and 5-fluorouracil (5-Fu) 300 mg/m2 1 week after the 
implantation. The chemotherapy was a 5- day schedule which contained gemcitabine on the 
first day followed by 4 days of 5-Fu. The chemotherapy was repeated every 4 weeks for up 
to six cycles if tolerated. 
7.2 External beam radiotherapy (EBRT) 
EBRT was generally recommended to all patients for an adjuvant aim. The patient received 
EBRT at 4–6 weeks after 125I seed implantation. The total doses of EBRT ranged from 35 to 50 
Gy at 1.8–2.0 Gy per fraction if tolerated. 
8. Clinical benefit response (CBR) 
The clinical benefit response assessment in these patients with locally advanced pancreatic 
cancer was derived from the measurement of pain levels, functional impairment (assessed 
by the Karnofsky performance status score), and weight loss (Burris et al., 1997). For patients 
to achieve an overall rating of positive CBR, they had to be positive for at least one 
parameter (pain, performance, status, or weight) without being negative for any of the 
others (Hwang et al., 2004). This improvement had to last for at least 4 weeks. Patient 
survival, tumor responses, and the clinical benefit responses were recorded. Visual analog 
scale (VAS) pain score was recorded as level 0 to 10, in which 0 indicated no pain, 1 to 3 
indicated mild pain, 4 to 7 meant moderate pain, and 8 to 10 severe pain. Scoring began after 
125I seeds were implanted.  
9. Evaluation of curative effect 
Patients were monitored for adverse events and for abnormalities in laboratory indices, 
including hematological parameters, lipase, amylase, carcinoembryonic antigen (CEA), 
CA19-9, and liver function tests. They were assessed by physical examination (including 
weight, Karnofsky performance status, and visual analog scale pain score), and the tumor 
size was monitored by CT scan or EUS. Patients were examined by CT 2 month after the 
operation. The short−term efficacy was determined according to the tumor response 
standards suggested by the World Health Organization (Miller et al., 1981). Briefly, 
complete response (CR) was defined as the complete disappearance of the lesion lasting for 
more than 4 weeks. Partial response (PR) referred to the situation where the size (i.e., the 
longest dimension multiplied by maximal upright dimension) of the lesion decreased by 
more than 50% and then remained unchanged for 4 weeks. Stable disease (SD) was defined 
as the situation where the size of the tumor decreased by less than 50% or increased by less 
than 25%. Response rate was defined as the sum of CR and PR. Local tumor control after 
brachytherapy was defined as the absence of tumor progression in CT (SD+PR+CR). The 
long−term efficacy included the median survival time, tumor−free survival, and 1−year 
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survival rate. Serum CA19–9 level was checked every month post-implantation as an 
indicator of prognosis. 
10. Follow-up 
The tumor diameter, general condition, and pain score of patients were monitored and 
recorded during follow−up. KPS and visual analog scale (VAS) pain score were used as the 
main indicators of quality of life (Burris et al., 1997; Hwang et al., 2004). VAS scoring began 
when chemotherapy started (1 week after brachytherapy). One month after seed 
implantation, patients were evaluated by radiation oncologists and surgeons by physical 
examination, complete blood panel, chest X-ray, abdominal CT and ultrasound. One month 
later, a clinical consultation was provided. After that, evaluation was given every 2–3 
months or sooner if a new clinical sign or symptom appeared. Time of survival was 
calculated from the date of diagnosis to the date of death or last follow-up. A local 
recurrence was defined as tumor progression (PD) within the implanted area or 
surrounding regions as seen on CT. Local recurrence and distant metastasis were scored 
until patient death and censored thereafter. The short term efficacy was determined 
according to the tumor response standards suggested by the World Health Organization. 
The long term efficacy included the median survival time, tumor−free survival, and survival 
rate. 
11. Complications 
The significant causes of high morbidity of 125I seed intraoperative implantation were due to 
the needles penetrated into pancreatic duct, small blood vessels in the pancreas and/or organ 
at risk resulting in fistula and abscess formation. The major long-term complication from the 
combined effects of multimodality treatments has been gastrointestinal bleeding and 
obstruction (Shipley et al., 1980).Clinical evaluation, ultrasound, and CT scans determined that 
the majority of patients developed metastases to the liver and peritoneal surface.  
12. Clinical status and prospects 
The survival for patients with pancreatic cancer remains poor despite standard surgical 
approaches, new adjuvant therapeutic techniques, and combined modality treatment. The 
treatment of unresectable pancreatic cancer continues to be a major challenge. More than 
half of patients have a locally or regionally confined tumor requiring local treatment. 
Resection of primary pancreatic malignancies with a curative intention is only feasible in 
less than 15% of all patients (Barkin & Goldstein, 2000). Most patients will have unresectable 
disease even before the diagnosis is made. The median survival time for untreated patients 
is 4 months, and they will suffer in varying degrees from pain, anorexia, weight loss, 
jaundice, and intestinal obstruction (Korinthenberg et al., 2011; Jiang et al., 2010). The 
management of these patients is still controversial. Combined modality treatment may have 
a positive effect on survival and quality of life in this group of patients.  
Traditional treatment for local control of advanced or metastatic pancreatic cancer involves 
intravenous chemotherapy with 5-fluorouracil (5-Fu) or gemcitabine; however, local 
recurrence and progression in the pancreas and peripancreatic lymph nodes under this 
treatment has been reported to be as high as 58% (Xie et al., 2006). Stereotactic radiotherapy 
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(SRT) allows an escalation of radiation doses to be applied to a small target volume within a 
small margin. SRT is administered in one or a few fractions with the goal of sparing the 
surrounding normal tissue by using multiple non-coplanar field arrangements for the 
administration. In a phase II study on the use of SRT in the treatment of locally advanced 
pancreatic carcinoma by Huyer et al, the median survival time was only 5.7 months, and the 
one-year survival rate was 5% (Gudjonsson, 1987). These data associate SRT with a poor 
outcome, unacceptable toxicity, and questionable palliative effects, making SRT unadvisable 
for patients with advanced pancreatic carcinoma. 
In the context of multimodal oncologic therapy concepts a minimally invasive approach is 
often desired. Percutaneous image-guided seed implantation which can be performed 
without surgery or general anesthesia has attracted increasing attention because of its ability 
to increase radiation dose to pancreatic tumors without damaging neighboring organs 
(Peretz et al., 1989). With this technique, highly effective radiation doses are applied as a 
single fraction, ensuring protracted cell killing over a period of up to several weeks or 
months. Compared with other interventional procedures, advantages exist regarding 
interference-free and accurately predictable energy distribution, treatable size of a target 
lesion, and lower rate of acute adverse effects possible by maintaining tissue continuity. 
Extensive experiences with this technique had been collected during several preceding 
studies targeting liver malignancies as well as one study targeting lung malignancies 
(Korinthenberg et al., 2011; Jiang et al., 2010; Xie et al., 2006) 125I seed placement has become 
a routine treatment for malignant tumors at various sites.  
In contrast, interstitial permanent implantation of radioactive seeds into the tumor site 
provides the advantage of delivering a high dose of irradiation to the tumor (range 140–160 
Gy) which drops off sharply outside the local implanted field. 125I seeds with a half-life of 
approximately 59.6 days were selected as the radioactive source for permanent implantation 
in this study, allowing approximately 95% of the needed dose to be delivered within a year 
(Hoyer et al., 2005). Implantation of radioactive isotopes for the treatment of pancreatic 
carcinoma has been used for the past several decades. For example, Handly et al. reported 
the use of radium needle implantation in 7 patients for the treatment of pancreatic 
carcinoma in 1934 (Hilaris, 1975). Of those, one patient survived up to two years. Hilaris, 
who was a pioneer in the development of 125I seeds for implantation for the treatment of 
pancreatic carcinoma, published a study of 98 patients receiving seed implants that 
responded with a median survival of 7 months (Handley, 1934), with 1 patient surviving for 
five years. Pain control was achieved in 65% of patients and lasted between 5 and 47 months 
(with a median of 6 months). In a review study by Morrow et al., no difference in survival 
between patients treated with interstitial brachytherapy and patients treated by surgical 
resection at the same institution were observed (Hilaris, 1975). The median survival time 
was 7 months, and at least one patient survived up to five years. Pain control was achieved 
in 65% of the patients (Morrow et al., 1984). Syed et al. reported 18 patients treated with 
biliary bypass surgery, 125I interstitial brachytherapy, and EBRT (Syed et al., 1983). Ten 
patients with the interstitial brachytherapy were "sandwiched" between two courses of 
EBRT. Typically, patients received 30 Gy EBRT following biopsy and bypass surgery, then 2 
weeks later an additional interstitial brachytherapy of 100–150 Gy, and then an additional 
15–20 Gy EBRT was administered 3–4 weeks after interstitial implantation. The results 
showed a 13 month median survival time in 12 patients with head and body pancreatic 
carcinoma. 125I seed implantation has been attempted in patients with locally advanced 
pancreatic carcinoma, and no difference in overall survival was found compared with the 
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use of other techniques (Morrow et al., 1984). Wang et al. reported 14 patients treated with 
125I seed implantation guided by intraoperative ultrasound (Wang et al., 2009). The 
interstitial needle position and distribution were determined using ultrasound supervision 
and with the intent to spare at least 1 cm from nearby or normal tissues including the 
internal pancreatic duct and small blood vessels. The placement of an omental fat pad over 
the implanted volume was also used to protect the gastric and transverse colon mucosa 
from irradiation. The result indicates that the local control of disease was achieved in 78.6% 
of all patients. 87.5% (7/8) of all patients experienced complete and partial pain relief and 
shown satisfactory palliative effect. The overall 1-, 2- and 3-year survival rates were 33.9%, 
16.9% and 7.8%, respectively with the median survival of 10 months. The survival rate and 
survival times were found to be the most advantageous for some selected stage II/III 
patients.  
However, there are few reports on CT-guided implantation of radioactive seeds in the 
treatment of pancreatic cancer. At present, the most commonly used isotope is 125I, and 125I 
placement has become a routine treatment for recurrent tumors at various sites. Wang et al. 
reported in this group of pancreatic cancer patients (Wang et al., 2010). 31 patients 
implanted 125I seeds under CT guidance and yielded good local control of the disease. The 
results showed even distribution of the radioactive seeds with overall response rate of 
61.3%, local control rate of 90.3%, and pain relief rate of 92%.  
Permanent interstitial administration of radioactive seeds appears to offer consistent and 
improved local control, although a major drawback is the high rate of perioperative 
morbidity and mortality. The significant causes of high morbidity of 125I seed intraoperative 
implantation were due to the needles penetrated into pancreatic duct, small blood vessels in 
the pancreas and/or organ at risk resulting in fistula and abscess formation. The major long-
term complication from the combined effects of multimodality treatments has been 
gastrointestinal bleeding and obstruction (Schwarz & Beger, 2000). The high incidence of 
complications maybe related to that the seeds were implanted nearby normal tissues such as 
gastric, colon and jejunum. The second reason may be the activity of seeds was high. The 
third reason maybe the doses of seeds beyond the tolerance of normal pancreas tissue. In 
earlier studies, perioperative mortality was 16% – 25% from acute pancreatitis, fistulization, 
and abscess formation (Peretz et al., 1989). Side effects reported in the Hilaris et al., study 
included 1 patient developing a post-operative mortality, another patient suffered from a 
pancreatic fistula, 4 patients developed biliary fistula, 4 developed abscesses, 4 developed 
gastrointestinal bleeding, 6 developed obstruction of the gastrointestinal tract, 5 patients 
developed sepsis, and 4 patients developed deep venous thrombophlebitis (Handley, 1934). 
In comparison, the study by Syed et al. included 8 patients with a poorer prognosis, 2 
patients with prolonged wound drainage, 3 patients developed insulin-dependent diabetes, 
and 2 patients developed other interstitial complications (Peretz et al., 1989). Also Wang et 
al. reported [48], one patient suffered from chylous fistula, one patient suffered from 
pancreatitis and one suffered from gastritis, seven patients suffered from low fever, there 
were no grade III and grade IV toxicity and complications, and less than most series of 
surgically-treated pancreatic cancer patients published in the literature (Morrow et al., 1984; 
Wang et al., 2009). 
Local complications of advanced pancreatic carcinoma result in significant morbidity and 
mortality. Although systemic therapy is ultimately needed for cure, an effective locoregional 
therapy for the treatment of the pancreatic primary and/or regional metastases in the liver 
would be beneficial in patients who do not have extensive extrahepatic disease at the time of 
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presentation. Current therapies, however, are of limited benefit in most patients. The high 
incidence of complications associated with resection of advanced pancreatic cancer and the 
significant gastrointestinal toxicity of external−beam radiation limit their usefulness (Yao et 
al., 2002). Other series of intraoperative iodine−125 implantation have been associated with 
mortality ranging from 0% to 16% and major morbidity of 18% (Order et al., 1996). Sun S et 
al. reported (Sun et al., 2006), there was no significant immediate complications, such as 
significant bleeding or infection. The incidence of complications was 3/15 (20%), and the 
adverse events were mild and not life−threatening. Although the objective response rate in 
patients with locally advanced pancreatic cancer was moderate, five patients experienced 
clinical benefit and four patients showed a partial tumor response. Pancreatic fistula is the 
most common complication after implantation of seeds, especially in surgery cases. In 
contrast, the needle used in EUS is thinner and the procedure is real−time monitored by 
EUS. Therefore, no pancreatic fistulae were observed in the present study. 
Nevertheless there were fewer complications compared with other interventional ablation 
procedures. From these data it appeared that 125I implantation of unresectable pancreatic 
tumors offered high control of the primary tumor and significant palliation of symptoms. 
Wang et al. reported (Wang et al., 2010), their data suggest that local control rates can be 
enhanced by the addition of chemotherapy. Despite lacking definitive proof, positive results 
allow us to continue the use of drug–seeds combination therapy. Cron et al. (Cron et al., 
2005) suggested that the best time for chemotherapy is within 3–4 days after implantation of 
125I seeds, because the permeability of the surrounding vasculature is promoted by the 
radiation effects of the seeds at that time. Wang et al. reported ten out of 31 patients in this 
group underwent additional chemotherapy 1 week post-treatment and tolerated it well 
(Wang et al., 2010). The median survival time for pure seeds implantation and drug–seeds 
combined therapy was 7 months and 11 months, respectively; it reached statistically 
significant and therefore encouraged our further evaluation. In the present study, 
implantation of seeds combined with chemotherapy in the treatment of pancreatic 
carcinoma showed preliminary effects. Although no complete remission cases were 
observed, the tumor progression was effectively controlled (stable disease or partial 
remission) in more than half of the patients (59.1%) (Jin et al., 2008). 
After promising results, we will further evaluate interventional brachytherapy as an 
additional tool in multimodal oncologic therapy concepts (Chen et al., 1999; Trombetta et al., 
2008). This study suggested that image-guided brachytherapy using 125I seeds implantation 
appeared to be safe, effective, uncomplicated, and could produce adequate pain relief for 
treating unresectable pancreatic cancer. The present study is limited: a multimodality 
approach, with image guided−interstitial brachytherapy in combination with chemotherapy 
or external radiation, may be indicated and should be tested in further studies. Therefore, 
future studies should be focused on how to design a mature and feasible integrated protocol 
based on radioactive seeds. 
13. In conclusion 
This study suggested that image-guided brachytherapy using 125I seeds implantation 
appeared to be safe, effective, uncomplicated, and could produce adequate pain relief for 
treating unresectable pancreatic cancer. 125I seed implantation with image-guided provides a 
satisfactory distribution of seeds in tumor mass, minimizes radiation to surrounding organs 
due to the sharp dose fall-off outside the implanted volume, and generates no damage 
(Armstrong et al., 1994). We hypothesize that a further improvement in median survival of 
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patients with unresectable pancreatic carcinoma may be obtained with the combined 
aggressive use of EBRT, systemic chemotherapy. 
14. Examples of clinical application 
 
 
 
 
 
 
   
   
   
 
 
 
 
 
Fig. 3. 80-year-old female patient. Pancreatic carcinoma patient with 125I seeds implant 
under CT guidance. (a)PTCD shows the lower common bile duct stenosis (arrow), while the 
upper common bile duct and intrahepatic bile ducts shows expansion. (b) Common bile 
duct stent is implanted (arrow). (c) Contrast CT done prior to 125I seeds implantation 
revealed mass measured around 1.7×1.8cm at head of pancreas (arrow), adjacent vessels and 
important organs were showed clearly on the film. (d-f) Puncture needle was inserted 
precisely to the tumor through subcutaneous tissue under CT guidance, and 125I seeds were 
implanted (arrows). (g) 2 months follow-up. Repeated contrast CT showed reduced size of 
mass and aggregation of 125I seeds (arrow). (h) 4 months follow-up. Pancreatic mass showed 
stabilization with repeated contrast CT (arrow). (i) 6 months follow-up. Repeated contrast CT 
showed increased size of mass (arrow) and ascites. 
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Fig. 4. 69-year-old male patient. Pancreatic carcinoma patient with 125I seeds implant under 
CT guidance. (a) Contrast CT done prior to 125I seeds implantation revealed mass measured 
around 2.1×2.6cm at the head of pancreas (arrow), adjacent vessels and important organs 
were showed clearly on the film. (b) PTCD shows the lower common bile duct stenosis 
(arrow), while the upper common bile duct and intrahepatic bile ducts show expansion. (c-
d) Puncture needle was inserted precisely to the tumor through subcutaneous tissue under 
CT guidance, and 125I seeds were implanted (arrows). (e) 6 months follow-up. Repeated 
contrast CT showed reduced size of mass and aggregation of 125I seeds (arrow). (f) 12 months 
post 125I seed implantation, repeated contrast CT showed reduced size of mass and 
aggregation of 125I seeds, pancreatic mass showed stabilization (arrow). 
 
 
 
   
 
 
Fig. 5. 76-year-old male patient. Pancreatic carcinoma patient with 125I seeds implant under 
CT guidance. (a) Contrast CT done prior to 125I seeds implantation revealed mass measured 
around 3.5×5.5cm at the body and tail of pancreas  (arrow), adjacent vessels and important 
organs were showed clearly on the film. (b) Puncture needle was inserted precisely to the 
tumor through subcutaneous tissue under CT guidance, and 125I seeds was implanted then 
(arrow). (c) 2 months follow-up. Repeated contrast CT showed reduced size of mass and 
aggregation of 125I seeds (arrow).  
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Fig. 6. 57-year-old female patient. Pancreatic carcinoma patient with 125I seeds implant 
under CT guidance. (a) Contrast CT done prior to 125I seeds implantation revealed mass 
measured around 4.5×5.5cm at the tail of pancreas (arrow), adjacent vessels and important 
organs were showed clearly on the film. (b) 12 months follow-up. Repeated contrast CT 
showed reduced size of mass and aggregation of 125I seeds (arrow). (c) 24 months follow-up. 
Repeated contrast CT showed reduced size of mass and aggregation of 125I seeds (arrow). 
Pancreatic mass showed stabilization. 
 
 
   
  
 
 
Fig. 7. 56-year-old female patient. Pancreatic carcinoma patient with 125I seeds implant 
under CT guidance. (a) Contrast CT done prior to 125I seeds implantation revealed mass 
measured around 4.5×6.5cm at the body and tail of pancreas (arrow), adjacent vessels and 
important organs were showed clearly on the film. (b) Puncture needle was inserted 
precisely to the tumor through subcutaneous tissue under CT guidance, and 125I seeds was 
implanted then (arrow). (c) Puncture needle reached precisely from prerenal space to the 
body and tail of pancreas cancer, which as far as possible to avoid the intestinal lumen 
(arrow). (d) CT 2Dimensional reconstruction after 125I seeds implantation was done to 
determine the distribution of 125I seeds (arrow). At the same picture the duodenal stent can 
be seen (curved arrow). (e) 2 months follow-up. Repeated contrast CT showed reduced size 
of mass and aggregation of 125I seeds (arrow).  
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Fig. 8. 78-year-old male patient. Pancreatic carcinoma patient with 125I seeds implant under 
CT guidance. (a) Contrast CT done prior to 125I seeds implantation revealed mass measured 
around 3.5×4.5cm at the head of pancreas (arrow), adjacent vessels and important organs 
were showed clearly on the film. (b) Puncture needle was inserted precisely to the tumor 
through subcutaneous tissue and stomach under CT guidance, and 125I seeds was implanted 
then (arrow). (c-d) CT 2Dimensional reconstruction after 125I implantation was done to 
determine the distribution of 125I seeds (arrows). (e) 2 months follow-up. Repeated contrast 
CT showed reduced size of mass and aggregation of 125I seeds (arrow). (f) 12 months follow-
up. Repeated contrast CT showed reduced size of mass and aggregation of 125I seeds, 
pancreatic mass showed stabilization (arrow.)   
 
  
  
 
Fig. 9. 56-year-old female patient. Pancreatic carcinoma patient with 125I seeds implant 
under CT guidance. (a) Preoperative contrast-enhanced CT scan shows a 3.5cmｘ4.5cm 
tumor at the head of pancreatic carcinoma (arrow). (b) CT scan shows that 125I seeds are 
implanted into the tumor via 18G implantation needles (arrow). (c) CT scan shows the 
distribution of 125I seeds post implantation (arrow). (d) 2 months follow-up. CT scan shows 
pancreatic tumor partially decreased and 125I seeds gathered together (arrow). 
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Fig. 10. 70-year-old male patient. Pancreatic carcinoma patient with 125I seeds implant under 
CT guidance. (a) Preoperative contrast-enhanced CT scan shows a 3.0cmｘ3.0cm tumor at 
the body of pancreatic carcinoma (arrow). (b) CT scan shows that 125I seeds are implanted 
into the tumor via 18G implantation needles (arrow). (c) CT scan shows the distribution of 
125I seeds post implantation (arrow). (d) 2 months follow-up. CT scan shows pancreatic 
tumor partially decreased and 125I seeds gathered together (arrow). 
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Currently there have been many armamentaria to be used in cancer treatment. This indeed indicates that the
final treatment has not yet been found. It seems this will take a long period of time to achieve. Thus, cancer
treatment in general still seems to need new and more effective approaches. The book "Current Cancer
Treatment - Novel Beyond Conventional Approaches", consisting of 33 chapters, will help get us physicians as
well as patients enlightened with new research and developments in this area. This book is a valuable
contribution to this area mentioning various modalities in cancer treatment such as some rare classic
treatment approaches: treatment of metastatic liver disease of colorectal origin, radiation treatment of skull
and spine chordoma, changing the face of adjuvant therapy for early breast cancer; new therapeutic
approaches of old techniques: laser-driven radiation therapy, laser photo-chemotherapy, new approaches
targeting androgen receptor and many more emerging techniques.
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